A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
Public ClinicalTrials.gov record NCT02649556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 26-week Extension Study to Determine the Biological and Functional Changes in Healthy Smokers Who Switched From Conventional Cigarettes (CC) to Tobacco Heating System 2.2 (THS 2.2) Compared to Those Who Continued to Smoke CC in the ZRHR-ERS-09-US Study
Study identification
- NCT ID
- NCT02649556
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Philip Morris Products S.A.
- Industry
- Enrollment
- 672 participants
Conditions and interventions
Conditions
Interventions
- CC Other
- THS 2.2 Other
Other
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2015
- Primary completion
- Mar 12, 2017
- Completion
- Dec 19, 2017
- Last update posted
- Dec 3, 2020
2015 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Celerion Arizona | Tempe | Arizona | 85283 | — |
| Clinical Research West Florida | Clearwater | Florida | 33765 | — |
| Covance, Inc | Daytona Beach | Florida | 32117 | — |
| Compass Research | Orlando | Florida | 32806 | — |
| Clinical Research West Florida | Tampa | Florida | 33603 | — |
| Compass Research | The Villages | Florida | 32162 | — |
| Central Kentucky Research Associate | Lexington | Kentucky | 40509 | — |
| Celerion Lincoln | Lincoln | Nebraska | 68502 | — |
| PMG Research of Cary | Cary | North Carolina | 27518 | — |
| PMG Research of Charlotte | Charlotte | North Carolina | 28209 | — |
| PMG Research of Raleigh | Raleigh | North Carolina | 27609 | — |
| PMG Research of Wilmington | Wilmington | North Carolina | 28401 | — |
| Midwest Clinical Research | Dayton | Ohio | 45417 | — |
| PMG Research of Bristol | Bristol | Tennessee | 37620 | — |
| NOCCR | Knoxville | Tennessee | 37920 | — |
| Benchmark | Austin | Texas | 78705 | — |
| Benchmark | Fort Worth | Texas | 76135 | — |
| Benchmark | San Angelo | Texas | 76904 | — |
| National Clinical Research | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02649556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2020 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02649556 live on ClinicalTrials.gov.